First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Related Research units
Abstract
Bibliographical data
Original language | German |
---|---|
Article number | 9 |
ISSN | 0732-183X |
Publication status | Published - 2010 |
pubmed | 20177030 |
---|